Are changes in olanzapine-induced liver enzyme levels associated with GSTT1 , GSTM1 , GSTP1 , and OGG1 gene polymorphisms?
, , and 
| Mar 29, 2024
| Mar 29, 2024
About this article
Article Category: Original article
Published Online: Mar 29, 2024
Page range: 61 - 67
Received: Aug 01, 2023
Accepted: Feb 01, 2024
DOI: https://doi.org/10.2478/aiht-2024-75-3770
Keywords
© 2024 Aylin Elkama et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Liver enzyme levels in olanzapine-treated patients (N=30) measured at three time points
| 2.1 (1.4–3.4) | 3.4 (1.9–6.8) | 2.8 (1.7–4.9) | 0.239 | |
| 17.0 (11.0–20.2) |
25.0 (17.7–44.5) |
17.0 (13.7–24.0) |
||
| 19.5 (15.7–27.0) | 25.0 (17.0–39.2) | 19.0 (17.0–25.0) | 0.692 | |
Demographic and clinical characteristics of studied population (N=30)
| 36.7±14.1/19–63 | |
| Men | 8 (26.7 %) |
| Women | 22 (73.3 %) |
| 64.8±12.3 | |
| 165.1±8.0 | |
| 23.9±4.6 | |
| 10 (33.3 %) | |
Association between gene polymorphisms and ALT levels (U/L) measured at the three time points in olanzapine-treated patients (N=30)
| Positive | 16.5 (12.2–18.5) | 30.0 (15.7–43.2) | 19.0 (10.7–25.7) | 0.090 |
| Null | 17.5 (11.0–24.5) | 23.5 (17.7–46.0) | 16.0 (14.0–22.2) | 0.183 |
| p-value |
0.632 | 0.917 | 0.819 | |
| Positive | 16.5 (11.0–19.0) | 23.5 (16.7–34.2) | 18.0 (14.7–23.2) | 0.153 |
| Null | 17.5 (11.5–33.7) | 35.0 (18.7–46.0) | 14.5 (10.2–24.7) | 0.223 |
| p-value |
0.344 | 0.504 | 0.504 | |
| 17.0 (13.2–25.2) | 21.0 (16.7–34.7) | 17.0 (13.7–29.0) | 0.323 | |
| 15.0 (11.0–19.0) | 27.5 (19.0–45.5) |
18.0 (11.7–23.7) |
||
| p-value |
0.608 | 0.355 | 0.822 | |
| 16.5 (11.2–18.7) | 24.5 (17.2–38.5) | 17.0 (14.2–20.0) | 0.170 | |
| 17.0 (10.7–26.7) | 26.5 (17.2–51.0) | 19.0 (12.2–29.5) | 0.211 | |
| p-value |
0.918 | 0.697 | 0.697 | |
Association between gene polymorphisms and α-GST levels (μg/L) measured at the three time points in olanzapine-treated patients (N=30)
| Positive | 1.7 (1.0–3.3) | 2.8 (1.7–4.7) | 2.2 (1.7–5.7) | 0.717 |
| Null | 2.5 (1.4–3.5) | 4.2 (2.1–7.2) | 2.9 (2.0–4.3) | 0.311 |
| p-value |
0.368 | 0.415 | 0.692 | |
| Positive | 2.0 (1.3–2.8) | 2.9 (1.9–4.4) | 2.9 (2.1–4.9) | 0.186 |
| Null | 4.0 (1.4–9.8) | 6.4 (2.1–10.1) | 1.8 (1.4–6.5) | 0.607 |
| p-value |
0.118 | 0.156 | 0.420 | |
| 1.9 (1.3–2.8) | 2.9 (1.8–6.2) | 3.3 (1.7–6.5) | 0.395 | |
| 2.6 (1.4–4.2) | 4.0 (2.3–7.0) | 2.4 (1.7–3.4) | 0.305 | |
| p-value |
0.377 | 0.313 | 0.334 | |
| 2.8 (1.7–4.3) | 3.6 (1.9–7.4) | 2.9 (2.0–4.3) | 0.646 | |
| 1.6 (1.1–2.6) | 3.4 (1.8–6.2) | 2.3 (1.6–6.1) | 0.257 | |
| p-value |
0.077 | 0.580 | 0.728 | |
Association between gene polymorphisms and AST levels (U/L) measured at three predetermined time points in olanzapine-treated patients (N=30)
| Positive | 21.5 (16.5–29.2) | 24.5 (16.0–39.7) | 22.0 (16.2–32.0) | 0.770 |
| Null | 19.0 (14.0–26.2) | 25.5 (17.0–39.2) | 19.0 (17.7–21.0) | 0.765 |
| p-value |
0.545 | 0.662 | 0.305 | |
| Positive | 19.5 (15.7–24.5) | 22.5 (16.7–39.2) | 19.0 (16.7–25.0) | 0.955 |
| Null | 23.0 (15.0–35.7) | 33.0 (21.2–47.2) | 20.5 (18.0–30.2) | 0.368 |
| p-value |
0.420 | 0.185 | 0.565 | |
| 19.0 (15.7–25.0) | 24.5 (18.2–37.7) | 20.5 (17.0–29.7) | 0.982 | |
| 22.5 (15.0–27.0) | 27.5 (17.0–39.7) | 19.0 (16.5–21.7) | 0.399 | |
| p-value |
0.608 | 0.580 | 0.334 | |
| 19.0 (15.7–26.2) | 25.5 (17.5–39.7) | 19.5 (18.0–21.7) | 0.814 | |
| 21.0 (15.5–30.2) | 23.0 (16.5–39.2) | 19.0 (16.0–30.7) | 0.801 | |
| p-value |
0.667 | 0.580 | 0.984 | |
Olanzapine maintenance doses and distribution of gene polymorphisms in the study population (N=30)
| 0.13±0.052 | |
| 0.42±0.565 | |
| Positive | 12 (40.0 %) |
| Null | 18 (60.0 %) |
| Positive | 22 (73.3 %) |
| Null | 8 (26.7 %) |
| 14 (46.7 %) | |
| 16 (53.3 %) | |
| 16 (53.3 %) | |
| 14 (46.7 %) | |